BIOMÉRIEUX |
Market Closed -
Other stock markets
|
After market 12:29:18 pm | |||
| 99.3 EUR | +0.05% |
|
99.22 | -0.08% |
| 02:42pm | BioMérieux: the rebound gains momentum, an analyst reinforces its case | CF |
| Apr. 26 | BioMérieux: share price rises, analyst remains Buy | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3.9B 4.2B | Sales 2025 * | 4.19B 4.52B | Capitalization | 11.73B 12.64B |
|---|---|---|---|---|---|
| Net income 2024 * | 467M 503M | Net income 2025 * | 527M 568M | EV / Sales 2024 * | 2.94 x |
| Net cash position 2024 * | 263M 284M | Net cash position 2025 * | 444M 478M | EV / Sales 2025 * | 2.69 x |
| P/E ratio 2024 * |
25.7
x | P/E ratio 2025 * |
22.7
x | Employees | 13,696 |
| Yield 2024 * |
0.87% | Yield 2025 * |
1.01% | Free-Float | 36.21% |
More Fundamentals
* Assessed data
More news
Latest transcript on bioMérieux
More recommendations
More press releases
More news
| 1 day | +0.86% | ||
| 1 week | +1.42% | ||
| Current month | +0.10% | ||
| 1 month | -3.93% | ||
| 3 months | -2.44% | ||
| 6 months | +7.89% | ||
| Current year | -0.50% |
1 week
97.95
100.90
1 month
97.10107.30
Current year
94.26108.90
1 year
84.54108.90
3 years
77.48133.20
5 years
67.45144.80
10 years
25.44144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 16-10-31 |
| Chairman | 50 | 04-04-15 | |
| Director of Finance/CFO | 47 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 06-09-14 | |
| Director/Board Member | 63 | 04-12-31 | |
| Chairman | 50 | 04-04-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 0 M€ | -4.02% | ||
| 0.26% | 0 M€ | +3.32% | ||
| 0.24% | 5 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 99.3 | +0.05% | 126 188 |
| 24-05-09 | 99.25 | +0.15% | 45,551 |
| 24-05-08 | 99.1 | -0.70% | 70,365 |
| 24-05-07 | 99.8 | +0.40% | 73,190 |
| 24-05-06 | 99.4 | +0.71% | 54,656 |
Real-time Euronext Paris, May 10, 2024 at 08:43 am EDT
More quotes
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
2024-05-22
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
99.25
EUR
Average target price
113.4
EUR
Spread / Average Target
+14.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.50% | 12.64B | |
| -1.64% | 8.37B | |
| +0.41% | 5.37B | |
| +22.42% | 5.26B | |
| -2.03% | 4.58B | |
| -52.84% | 3.16B | |
| +20.02% | 2.89B | |
| -8.32% | 2.22B | |
| -2.45% | 1.91B | |
| +5.37% | 1.65B |
- Stock Market
- Equities
- BIM Stock